Premium
Endothelial dysfunction biomarker, endothelial cell‐specific molecule‐1, and pediatric metabolic syndrome
Author(s) -
Halici Iclal,
Palabiyik Saziye Sezin,
GuducuTufekci Fatma,
OzbekBilgin Asli,
Cayir Atilla
Publication year - 2016
Publication title -
pediatrics international
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.49
H-Index - 63
eISSN - 1442-200X
pISSN - 1328-8067
DOI - 10.1111/ped.12989
Subject(s) - medicine , metabolic syndrome , insulin resistance , triglyceride , endothelial dysfunction , biomarker , endocrinology , cholesterol , lipoprotein , hemoglobin , high density lipoprotein , gastroenterology , insulin , obesity , biochemistry , chemistry
Background The aim of this study was to compare serum endothelial cell‐specific molecule‐1 (endocan) in pediatric patients with metabolic syndrome (MetS) and in healthy children, and to determine whether it can be used as an indicator of endothelium damage‐induced complications in pediatric MetS patients. Methods The study included 30 patients, aged 6–16 years, who were diagnosed with MetS. Another 30 children with no diseases were recruited as healthy controls. Endocan concentration was measured using enzyme‐linked immunosorbent assay. Results Endocan was increased almost threefold in the MetS group compared with the healthy group. Systolic arterial tension and diastolic arterial tension, serum triglyceride, total cholesterol, and low‐density lipoprotein cholesterol were higher, and high‐density lipoprotein cholesterol was lower, in the MetS children than in the healthy group. Fasting blood glucose (FBG), hemoglobin A1c (HBA1C), and homeostasis model assessment insulin resistance (HOMA‐IR) were also significantly increased in the children with MetS compared with the healthy group. Conclusions Serum endocan level in pediatric MetS patients could be an important indicator of cardiovascular risk in adulthood.